

## COMMUNICATION ON TOTAL AMOUNT OF VOTING RIGHTS PURSUANT TO ARTICLE 85-BIS, PARAGRAPH 4-BIS, OF CONSOB REGULATION NO. 11971/1999

**Saluggia, July 7<sup>th</sup>, 2025** – Diasorin S.p.A. (“Diasorin” or the “Company”) hereby announces that some shareholders, holding equity interests lower than 3% of the overall voting rights – waived to the accrued increased voting rights, for overall no. 460 ordinary shares of the Company.

In accordance with Article 85-*bis* paragraph 4-*bis*, of Consob Regulation no. 11971/1999, the total amount of the voting rights is presented below, together with the number of shares making up the share capital:

	Status after assignment of increased voting rights			Status before assignment of increased voting rights		
	Number of shares making up share capital	No. of voting rights	Euro	Number of shares making up share capital	No. of voting rights	Euro
<b>Total amount, of which:</b>	55,948,257	88,250,630*	55,948,257	55,948,257	88,251,090*	55,948,257
<b>Ordinary shares without increased voting rights</b> ISIN IT0003492391 (regular dividend) Current coupon: no. 21	23,645,884	23,645,884	-	23,645,424	23,645,424	-
<b>Ordinary shares with increased voting rights</b> ISIN IT0005188385 (regular dividend) Current coupon: no. 21	32,302,373	64,604,746	-	32,302,833	64,605,666	-

\* As previously disclosed to the market, as a result of the approval of the proposal to enhance the current loyalty shares system by the Extraordinary Shareholders' Meeting of February 28, 2025, the right of withdrawal was exercised for 943,617 shares, for which the voting right is currently not exercisable.

The Special List, updated in accordance with Article 9-*quater* of the Company By-Laws, is

available on the Company website <https://int.diasorin.com/>, in the Section “Company/Governance/Ownership Structure/Loyalty shares”.

**About DiaSorin**

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 34 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at [www.diasorin.com](http://www.diasorin.com)

**FOR ADDITIONAL INFORMATION, PLEASE CONTACT:**

**INVESTOR RELATIONS**

**Riccardo Fava**

Corporate VP Communication, ESG & Investor Relations  
[riccardo.fava@diasorin.it](mailto:riccardo.fava@diasorin.it)

**Eugenia Ragazzo**

Corporate Investor Relations & ESG Analyst  
[eugenia.ragazzo@diasorin.it](mailto:eugenia.ragazzo@diasorin.it)